Aquestive Therapeutics, Inc. (AQST) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Aquestive Therapeutics, Inc. (AQST) closed at USD 4.61 on 2026-10-14, a change of -31.4 % over the past year, with a market capitalization of USD 509.58M.

Aquestive Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aquestive Therapeutics, Inc. key figures

Previous close

USD 4.61 (2026-10-14)

1-year change

-31.4 %

Market cap

USD 509.58M

Enterprise value

USD 470.12M

P/E ratio (trailing)

-7.12

P/E ratio (forward)

-7.12

EPS (trailing)

-0.57

EPS (forward)

-0.57

PEG ratio

n/a

Price to book

-9.00

Revenue growth

38.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.69

Employees

147

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aquestive Therapeutics, Inc. and compare it with other stocks.